

Two new cytotoxic acetogenins from *Annona squamosa*

Hai-Jun Yang¹, Xiang Li^{1*}, Ning Zhang, Jian-Wei Chen and Ming-Yan Wang

Department of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China

(Received 25 September 2008; final version received 4 December 2008)

Two new annonaceous acetogenins named as squamostanin-A and squamostanin-B were isolated from 95% EtOH extract of the seeds of *Annona squamosa*. Their structures were determined by spectroscopic method, and their cytotoxicities were evaluated using MTT method.

Keywords: *Annona squamosa*; annonaceous acetogenins; cytotoxic activity

1. Introduction

Annonaceous acetogenins (ACGs) constitute a series of natural products isolated exclusively from *Annonaceae* plants [1–5], which comprise of some 130 genera and include over 2300 species and are widely distributed in tropical and subtropical regions. The main chemical ingredients of *Annonaceae* plants are ACGs and alkaloids. Now, more than 500 ACGs have been isolated from *Annona* genus plant. ACGs exhibited a broad range of biological properties such as cytotoxic, antiparasitic, pesticidal, and immunosuppressive activities [6,7]. Especially, the ACGs have distinctive antitumor effects through the depletion of ATP levels via inhibiting complex I of mitochondria and inhibiting the NADH oxidase of plasma membranes of tumor cells [8,9]. In our investigation, two new ACGs were isolated from the seeds of *Annona squamosa*. In this paper, we report the isolation, structure elucidation, and cytotoxicities of two new ACGs (Figure 1).


2. Results and discussion

Compound **1** was obtained as a white amorphous powder. Its molecular formula

was determined to be C₃₇H₆₈O₈ by the ion peak at m/z 639.4698 [M + H]⁺ in the HR-EI-MS. The IR absorption bands at 3320, 1720, and 1524 cm⁻¹ showed the presence of hydroxyl, carbonyl, and double bond. In the ¹H NMR spectrum of **1**, the signals at δ 7.20 (1H, d, H-35), 5.07 (1H, dq, H-36), 2.26 (2H, t, H-3), and 1.38 (3H, d, H-37), together with the carbon signals at δ 174.5 (C-1), 152.2 (C-35), 134.5 (C-2), 79.5 (C-36), 25.4 (C-3), and 19.2 (C-37) are characteristic spectral data for the methyl α,β-unsaturated γ-lactone moiety, commonly found in the ACGs [10], which was also supported by the positive Kedde reaction. The presence of a non-adjacent bis-THF ring system with four flanking hydroxyls was indicated by the ¹H NMR signals at δ 3.83–3.93 (4H, m, H-11, 14, 19, 22), 3.31–3.40 (3H, m, H-15, 18, 23), and 3.40 (1H, m, H-27), and the ¹³C NMR signals at δ 80.9 (C-11), 84.0 (C-14), 83.8 (C-19), 83.9 (C-22), 75.5 (C-15), 75.3 (C-18), 75.1 (C-23), and 74.4 (C-27). In the high-field region of the ¹H and ¹³C NMR spectra, the proton signals at δ 1.23–1.76 (m) and the carbon signals at δ 14.4–32.6 showed the presence of long fatty chain. Furthermore, the EI-MS fragment ions at 539, 521, 503, 485, 467, 449, 431, 413, 367,


*Corresponding author. Email: yanghaijun19831009@163.com

¹Hai-Jun Yang and Xiang Li contributed equally to this manuscript.

Figure 1. Structures of compounds **1** and **2**.

and 349 showed the clearance process of compound **1** (Figure 2), the four successive losses of H₂O (*m/z* 18) in the EI-MS of **1** showed the existence of four OH moieties, and the positions of the OH groups in **1** were assigned at C-15, C-18, C-23, and C-27 by careful analysis of fragment ions in the EI-MS of **1** and its tetra-TMSi derivative (**1b**; Figures 2 and 3). The placement of the THF ring moiety was also established by the close examination of fragments ions in the EI-MS of **1** at *m/z* 467, 437, 367, and 279, and its tetra-TMSi derivative (**1b**) at *m/z* 683, 653, 511, and 279. Thus, the fragmentation pattern observed showed that the non-adjacent bis-THF ring moiety was located from C-11 to C-14 and C-19 to C-22, respectively (Figures 2 and 3).

The relative stereochemistry between C-14 and C-15 was indicated as *threo* by comparing the proton signals at H-14 (δ 3.83) and H-15 (δ 3.40) and carbon signals at C-14 (δ 84.0) and C-15 (δ 75.5) with those of known ACGs squamostanin-D [11]. The proton signals at δ 3.31 (H-18), 3.83 (H-19), 3.83 (H-22), and 3.34 (H-23) in the ¹H NMR spectrum of **1** suggested the relative stereochemistry of C-18–C-19 and C-22–C-23 was also *threo*. The ¹H and ¹³C NMR spectral data for the methines and methylenes in the rings suggested the relative configurations of the two THF rings were both *trans* [12,13]. Therefore, the relative stereochemistry across the THF ring and the flanking hydroxyls was assigned as *trans/threo/threo/trans/threo*

Figure 2. Diagnostic mass fragmentation ions of **1** and **2** (molecular mass = 638 amu) in *m/z*, losses of *m/z* 18 indicate the loss of H₂O neutrals.




Figure 3. Diagnostic mass fragmentation ions of **1b** and **2b** (molecular mass=926 amu) in m/z , losses of m/z 90 indicate the loss of TMSiOH neutrals.

which was consistent with that of squamostanin-D. Compound **1** is a structural isomer of squamostanin-D, their difference is the position of the THF ring system, the non-adjacent bis-THF ring of squamostanin-D is located at C-12–C-15 and C-20–C-23, respectively. Thus, the ring system of compound **1** is shifted by one carbon unit toward the γ -lactone ring. To determine the stereochemistry of compound **1**, the (*R*)- and (*S*)-Mosher ester derivatives were prepared, the negative value of δ_H (*S*–*R*) at H-14 (–0.072), H-15 (–0.011), H-17 (–0.017), H-18 (–0.039), H-22 (–0.066), H-23 (–0.054), H-26 (–0.014), and H-27 (–0.044) suggested the absolute stereochemistries were determined as C-15 *R*, C-18 *R*, C-23 *R*, and C-27 *R*, respectively, by using advanced Mosher ester methodology (Table 1). Comparing the NMR spectral data of the MTPA derivatives of **1** with those of model butenolides synthesized by Hoye *et al.* [14], the absolute stereochemistry for C-36 was determined as *S*, which was identical to all the known ACGs. Accordingly, the structure of compound **1** was elucidated as reported in Figure 1.

Compound **2** was obtained as a white wax powder. Its molecular formula was determined to be $C_{37}H_{68}O_8$ by the ion peak at m/z 639.4682 $[M + H]^+$ in the HR-EI-MS. The 1H and ^{13}C NMR spectral data of compound **2** were almost identical to those of compound **1** (Table 3), and the EI-MS of compound **2** was almost superimposable with that of

compound **1**. In the 1H NMR spectrum of **2**, the signals at δ 7.22 (1H, d, H-35), 5.13 (1H, dq, H-36), 2.27 (2H, t, H-3), and 1.37 (3H, d, H-37), together with the carbon signals at δ 172.5 (C-1), 151.8 (C-35), 133.5 (C-2), 79.8 (C-36), 24.3 (C-3), and 19.7 (C-37) also indicated the presence of methyl α,β -unsaturated γ -lactone moiety and the presence of a non-adjacent bis-THF ring system with flanking hydroxyls was also indicated by the 1H NMR signals at δ 3.80–3.89 (4H, m, H-11, 14, 19, 22), 3.37–3.42 (3H, m, H-15, 18, 27), and the ^{13}C NMR signals at δ 81.3 (C-11), 84.2 (C-14), 84.5 (C-19), 84.0 (C-22), 75.3 (C-15), 74.9 (C-18), and 74.3 (C-27), which showed the two compounds had a similar structure. However, comparing their 1H and ^{13}C NMR spectra carefully, their main differences were the chemical shifts of H-23 and C-23. In the 1H NMR spectra of **2** and **2a**, the proton signals at δ 3.82 (1H, m, H-23) and 3.84 (1H, m, H-23), respectively, and the carbon signal at δ 71.3 (C-23), indicated the relative stereochemistry between C-22 and C-23 was *erythro*. So, the relative stereochemistry of THF ring system of compound **2** was *trans/threo/threo/trans/erythro*. The (*R*)- and (*S*)-Mosher ester derivatives of compound **2** were also prepared to determine the absolute configuration and the positive value of δ_H (*S*–*R*) at H-19 (+0.046), H-22 (+0.066), and H-23 (+0.052) suggested an *S*-configuration at C-23 of compound **2**. Thus, the absolute stereochemistries of compound **2** were determined

Table 1. ¹H NMR (500 MHz, CDCl₃) spectral data for MTPA derivatives of compounds **1** and **2**.

H No.	14	15	16	17	18	19	22	23	24	26	27	28
δ _{1S}	3.890	5.006	1.746	1.720	5.108	3.880	3.902	5.300	3.934	1.882	5.120	1.685
δ _{1R}	3.962	5.017	1.721	1.737	5.147	3.922	3.968	5.354	3.920	1.896	5.164	1.664
δ _{1S-R}	-0.072	R	+0.025	-0.017	R	+0.042	-0.066	R	+0.014	-0.014	R	+0.021
δ _{2S}	3.886	5.106	1.766	1.726	5.168	3.932	3.978	5.300	3.890	1.852	5.070	1.687
δ _{2R}	3.925	5.167	1.731	1.737	5.184	3.886	3.912	5.248	3.914	1.879	5.104	1.674
δ _{2S-R}	-0.039	R	+0.035	-0.011	R	+0.046	+0.066	S	-0.024	-0.027	R	+0.013

as C-15 *R*, C-18 *R*, C-23 *S*, and C-27 *R* by using advanced Mosher ester methodology (Table 1). The NMR spectral data of the MTPA derivatives of **2** were compared with those of model butenolides synthesized by Hoyer *et al.* [14]. On the basis of the above analysis, the compound **2** is a structural isomer of compound **1** and the structure of compound **2** was elucidated as reported in Figure 1.

The cytotoxicities of compounds **1** and **2** were evaluated against the human tumor cell lines of human colon adenocarcinoma (HCT), human lung carcinoma (A-549), human breast carcinoma (MCF-7), and human prostate adenocarcinoma (PC-3) by the conventional MTT method. The results listed in Table 2 showed that both the compounds exhibited significant selective activities against all four human tumor cell lines in our 2-day MTT tests. As shown in Table 2, compound **2** showed notable selective activity against PC-3 tumor cells with an IC₅₀ value 7.33×10^{-4} μg/ml. Furthermore, the result of cytotoxicity bioassays showed compound **2** was generally more bioactive than compound **1**, whose cytotoxicities also exceeded adriamycin. The relative stereochemistry of ACGs may be an important factor for the bioactivity, and the ACGs with *threo/trans/threo/erythro* stereochemical arrangement showed to be gently more active than those with the *threo/trans/threo/trans/threo* stereochemical arrangement. The result of cytotoxicity bioassays also further revealed that the ACGs have a broad range of cytotoxic activity and ACGs have been judged as promising candidates for a future generation of drugs to fight against tumor cells.

3. Experimental

3.1 General experimental procedures

Melting points were determined on a Yanaco-MP-S3 micro melting point apparatus and are uncorrected. Optical rotations were measured on a Perkin-Elmer 241 MC polarimeter. The UV spectra were taken on a HP 8451A diode

Table 2. Cytotoxicity of **1** and **2** against human tumor cell lines.

Compound	ED ₅₀ (μg/ml)			
	HCT	A-549	PC-3	MCF-7
1	3.97×10^{-3}	5.67×10^{-3}	5.63×10^{-3}	1.62×10^{-2}
2	3.02×10^{-3}	5.53×10^{-3}	7.33×10^{-4}	1.17×10^{-2}
Adriamycin	4.94×10^{-2}	2.62×10^{-2}	2.87×10^{-1}	1.94×10^{-1}

array spectrophotometer. The IR spectra were recorded on a NEXUS-470 spectrophotometer. The ¹H and ¹³C NMR spectral data were recorded on Bruker ACF-300P in CDCl₃. EI-MS data were obtained on FEOL JMS 300S. HR-EI-MS data were obtained on a PE LC/MS spectrometer. Chromatography was performed on silica gel (200–300 mesh). Optical densities (OD) were read on a BR680 enzyme-labeled detector.

3.2 Plant material

The seeds of *A. squamosa* were collected from Guangdong Province in July 2007 and identified by Prof. Jian-Wei Chen (Nanjing University of Chinese Medicine, Jiangsu, China). The sample was authenticated and is deposited in the Pharmaceutical College of Nanjing University of Chinese Medicine, Jiangsu (No. 083).

3.3 Extraction and isolation

The seeds of *A. squamosa* (14 kg) were pulverized and then extracted three times with 95% EtOH for 2 h at room temperature. The extract (1400 g) was suspended in water and partitioned to provide petroleum ether (180 g), CHCl₃ (238 g), and *n*-BuOH (80 g) fractions, respectively. The CHCl₃ fraction (208 g) was subjected to Si-gel column chromatography (eluted with CHCl₃ and MeOH in increasing polarity) to obtain six fractions (H₁–H₆). The fraction H₂ was further fractioned on Si-gel column chromatography with a step gradient elution of CHCl₃–MeOH (100:1, 50:1, 20:1, and 10:1) to afford other 10 fractions (H₇–H₁₆). The fraction H₈ was further subjected to

Si-gel column chromatography gradiently eluted with CHCl₃–MeOH (50:1, 20:1, 10:1, and 2:1) to afford **1** (52 mg). The H₁₀ fraction was also further subjected to Si-gel column chromatography eluted with CHCl₃–MeOH (50:1, 20:1, 10:1, and 1:1) to afford **2** (61 mg).

3.3.1 Compound 1

White amorphous powder; mp 82–84°C; $[\alpha]_D^{25} +9.7$ ($c = 0.082$, MeOH); UV (MeOH) λ_{\max} : 220 nm ($\log \epsilon$ 4.27). IR (KBr) ν_{\max} (cm⁻¹): 3320, 1720, 1524, and 765. The ¹H and ¹³C NMR spectral data are reported in Table 3. EI-MS m/z : 638, 620, 539, 521, 503, 485, 467, 449, 431, 413, and 279. HR-EI-MS m/z : 639.4698 [M + H]⁺ (calcd for C₃₇H₆₆O₈, 639.4758).

3.3.2 Compound 2

White wax powder; mp 62–63°C; $[\alpha]_D^{25} +16.7$ ($c = 0.067$, MeOH). UV (MeOH) λ_{\max} : 220 nm ($\log \epsilon$ 4.20). IR (KBr) ν_{\max} (cm⁻¹): 3220, 1715, 1545, and 762. The ¹H and ¹³C NMR spectral data are reported in Table 3. EI-MS m/z : 638, 620, 539, 521, 503, 485, 467, 449, 431, 413, 367, 349, and 279. HR-EI-MS m/z : 639.4682 [M + H]⁺ (calcd for C₃₇H₆₆O₈, 639.4758).

3.4 Preparation derivatives

3.4.1 Preparation of tri-TMSi derivatives

Pure compounds **1** and **2** (25 mg) were placed in a 100 ml conical reaction vial, respectively, and dried in a vacuum desiccator over P₂O₅ for 24 h. The sample was treated with 2 μl of pyridine and 20 μl of *N,O*-bis(trimethylsilyl)

Table 3. ¹H NMR and ¹³C NMR spectral data of compounds **1** and **2** and their tetra-acetate derivatives **1a** and **2a** (500 MHz, CDCl₃, *J* in Hz and δ in ppm).

H/C No.	δ_{H} (J, Hz)			δ_{C}	
	1	1a	2	1	2
1	—	—	—	174.5	172.5
2	—	—	—	134.5	133.5
3	2.26 (2H, t, 7.2)	2.22 (2H, t, 7.2)	2.27 (2H, t, 7.2)	25.4	24.3
4	1.27 (2H, m)	1.17–1.38	1.23 (2H, m)	27.6	26.7
5–10	1.26–1.56 (m)	1.22–1.77 (m)	1.21–1.55 (m)	26.3–30.6	25.4–29.7
11	3.93 (1H, m)	4.87 (1H, m)	3.89 (1H, m)	80.9	81.3
12	1.96 (2H, m)	2.07 (2H, m)	1.92 (2H, m)	25.9	26.1
13	1.97 (2H, m)	2.07 (2H, m)	1.95 (2H, m)	27.0	27.7
14	3.83 (1H, m)	3.86 (1H, m)	3.87 (1H, m)	84.0	84.2
15	3.40 (1H, m)	4.82 (1H, m)	3.42 (1H, m)	75.5	75.3
16	1.74 (2H, m)	1.74 (2H, m)	1.71 (2H, m)	33.0	33.2
17	1.72 (2H, m)	1.74 (2H, m)	1.72 (2H, m)	31.2	30.8
18	3.31 (1H, m)	4.80 (1H, m)	3.37 (1H, m)	75.3	74.9
19	3.83 (1H, m)	3.85 (1H, m)	3.80 (1H, m)	83.8	84.5
20	1.92 (2H, m)	1.98 (2H, m)	1.91 (2H, m)	28.2	28.7
21	1.95 (2H, m)	1.96 (2H, m)	1.93 (2H, m)	28.3	29.1
22	3.83 (1H, m)	3.85 (1H, m)	3.86 (1H, m)	83.9	84.0
23	3.34 (1H, m)	4.82 (1H, m)	3.82 (1H, m)	75.1	71.5
24	1.74 (2H, m)	1.80 (2H, m)	1.65 (2H, m)	35.5	33.6
25	1.77 (2H, m)	1.80 (2H, m)	1.71 (2H, m)	30.3	30.1
26	1.75 (2H, m)	1.81 (2H, m)	1.72 (2H, m)	31.6	31.5
27	3.40 (1H, m)	4.88 (1H, m)	3.37 (1H, m)	74.4	74.3
28	1.73 (2H, m)	1.78 (2H, m)	1.71 (2H, m)	30.8	30.6
29	1.43 (2H, m)	1.48 (2H, m)	1.45 (2H, m)	29.2	28.7
30	1.42 (2H, m)	1.48 (2H, m)	1.46 (2H, m)	29.7	29.6
31	1.41 (2H, m)	1.47 (2H, m)	1.43 (2H, m)	27.0	27.3
32	1.42 (2H, m)	1.47 (2H, m)	1.44 (2H, m)	30.4	30.6
33	1.36 (2H, m)	1.43 (2H, m)	1.38 (2H, m)	23.7	23.2
34	0.90 (3H, t, 7.2)	0.90 (3H, t, 7.2)	0.93 (3H, t, 7.2)	14.4	14.4
35	7.20 (1H, d, 1.5)	7.24 (1H, d, 1.5)	7.22 (1H, d, 1.5)	152.2	151.8
36	5.07 (1H, dq, 7.2, 1.5)	5.07 (q, 7.2)	5.13 (1H, dq, 7.2, 1.5)	79.5	79.8
37	1.38 (3H, d, 7.2)	1.38 (3H, d, 7.2)	1.37 (3H, d, 7.2)	19.2	19.7
OAC	—	2.06 (6H, S)	—	—	—
	—	2.08 (6H, S)	—	—	—

acetamide and heated at 70°C for 30 min to yield the tetra-TMSi derivatives (**1b** and **2b**).

3.4.2 Preparation of *per-S*- and *per-R*-Mosher esters

Purified compounds **1** and **2** (2.0 mg) were dissolved in 0.5 ml of CH₂Cl₂ and sequentially, 0.2 ml of pyridine, 0.2 mg of 4-(dimethylamino) pyridine, and 25 mg of (*R*)-(-)- α -methoxy-(trifluoromethyl) phenylacetyl chloride were added. The mixture was left at room temperature for 4 h and purified over a microcolumn (0.66 cm) of Si-gel eluted with 2 ml of CH₂Cl₂. The eluate was washed with 1% NaHCO₃ (5 ml) and H₂O (2 \times 5 ml) and dried *in vacuo* to give the *S*-Mosher esters. Use of (*S*)-(+)- α -methoxy- α -(trifluoromethyl) phenylacetyl chloride gave the *R*-Mosher ester derivatives of compounds **1** and **2**.

3.4.3 Preparation of acetate derivatives

Pure compounds **1** (10 mg) and **2** (12 mg) were dissolved in 0.5–1.0 ml of pyridine, respectively. Anhydrous Ac₂O (1 ml) was added and the mixture was left at room temperature for 4–8 h. The mixture was then partitioned between H₂O and CH₂Cl₂, and the organic layer was concentrated *in vacuo* to afford the pure acetate derivatives (**1a** and **2a**).

3.5 Cytotoxicity assays

Compounds **1** and **2** were assayed for cytotoxicity against HCT, human lung carcinoma (A-549), human breast carcinoma (MCF-7), and human prostate adenocarcinoma (PC-3) with adriamycin as positive standard using MTT method. Freshly trypsinized cell suspensions were seeded in a 96-well microtiter plate at a density of 6000–10,000 cell/ml, and different concentrations of compounds **1** and **2** stocks were added after 24 h seeding.

The microtiter plates were incubated for 48 h in a humidified atmosphere of 5% CO₂ at

37°C and the cellular viability was determined using a standard MTT method, the OD were read on an enzyme-labeled detector (BR680) at a wavelength of 490 nm.

Acknowledgements

The authors acknowledged Prof. Jian-Wei Chen for identifying the seed of *A. squamosa* and Prof. Ming-Yan Wang for cytotoxicity test guidance.

References

- [1] M.C. Zafra-Polo, M.C. González, E. Estornell, S. Sahpaz, and D. Cortes, *Phytochemistry* **42**, 253 (1996).
- [2] M.C. Zafra-Polo, B. Figadère, T. Gallardo, J.R. Tormo, and D. Cortes, *Phytochemistry* **48**, 1087 (1998).
- [3] L. Zeng, Q. Ye, N.H. Oberlies, G. Shi, Z.M. Gu, K. He, and J.L. McLaughlin, *Nat. Prod. Rep.* **13**, 275 (1996).
- [4] F.Q. Alali, X.X. Liu, and J.L. McLaughlin, *J. Nat. Prod.* **62**, 504 (1999).
- [5] J.R. Tormo, T. Gallardo, M.C. González, A. Bermejo, N. Cabedo, I. Andreu, and E. Estornell, *Curr. Top. Phytochem.* **2**, 69 (1999).
- [6] A. Yazbak, S.C. Sinha, and E. Keinan, *J. Org. Chem.* **63**, 5863 (1998).
- [7] F.Q. Alali, L. Rogers, Y. Zhang, J.L. McLaughlin, F.Q. Alali, L. Rogers, and J.L. McLaughlin, *J. Nat. Prod.* **21**, 36 (1999).
- [8] M. Londershausen, W. Leicht, F. Lieb, H. Moeschler, and H. Weiss, *Pestic. Sci.* **33**, 427 (1991).
- [9] M. Degli Esposti, A. Ghelli, M. Ratta, D. Cortes, and E. Estornell, *J. Biochem.* **161**, 301 (1994).
- [10] M.C. Zafra-Polo, M.C. Gonzalez, E. Estornell, S. Sahpaz, and D. Cortes, *Phytochemistry* **42**, 253 (1996).
- [11] R.Z. Yanf, X.C. Zheng, S.J. Wu, W.X. Yi, and X.H. Hui, *Act. Botanic. Yunnanica* **21**, 517 (1999).
- [12] M.H. Woo, K.Y. Cho, Y. Zhang, L. Zeng, Z.M. Gu, and J.L. McLaughlin, *J. Nutr. Prod.* **58**, 1533 (1998).
- [13] G.X. Zhao, Z.M. Gu, L. Zeng, J.F. Chao, J.F. Kozlowski, K.V. Wood, and J.L. McLaughlin, *Tetrahedron* **51**, 7149 (1995).
- [14] T.R. Hoye, P.R. Hanson, L.E. Hasenwinkel, E.A. Ramirez, and Z.P. Zhuang, *Tetrahedron Lett.* **35**, 8529 (1994).

Copyright of *Journal of Asian Natural Products Research* is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.